伐努賽珠單抗

**伐努賽珠單抗**
單克隆抗體
種類	完整抗體
目標	血管生成素2
臨床資料
其他名稱	RG7221
ATC碼	未分配;
識別資訊
CAS號	1448221-05-3
ChemSpider	none;
UNII	B800Z06O8K;
KEGG	D11244;
化學資訊
化學式	C6529H10033N1733O2038S46
摩爾質量	146,887.94 g·mol−1

伐努賽珠單抗（INN：Vanucizumab；開發代號：RG7221）是一種實驗性人源化單克隆抗體，設計用於治療癌症。^[1]^[2]

伐努賽珠單抗是一種雙特異性單克隆抗體，由兩條不同的重鏈和兩條不同的輕鏈組成。該抗體的一個臂結合血管生成素2（Ang2），另一個臂基於貝伐珠單抗（Avastin），結合血管內皮生長因子A（VEGF-A）。該抗體旨在同時抑制VEGF-A和 Ang2，與單獨抑制VEGF-A相比，可提供更優異的臨床益處。^[3]

該藥物由基因泰克/羅氏公司開發。

參考資料[編輯]

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
^ Bendell, Johanna C.; Sauri, Tamara; Gracián, Antonio Cubillo; Alvarez, Rafael; López‐López, Carlos; García‐Alfonso, Pilar; Hussein, Maen; Miron, Maria‐Luisa Limon; Cervantes, Andrés; Montagut, Clara; Vivas, Cristina Santos. The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist. 2020-3, 25 (3). ISSN 1083-7159. PMC 7066709 . PMID 32162804. doi:10.1634/theoncologist.2019-0291. 請檢查|date=中的日期值 (幫助)

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.

[2] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).

[3] Bendell, Johanna C.; Sauri, Tamara; Gracián, Antonio Cubillo; Alvarez, Rafael; López‐López, Carlos; García‐Alfonso, Pilar; Hussein, Maen; Miron, Maria‐Luisa Limon; Cervantes, Andrés; Montagut, Clara; Vivas, Cristina Santos. The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist. 2020-3, 25 (3). ISSN 1083-7159. PMC 7066709 . PMID 32162804. doi:10.1634/theoncologist.2019-0291. 請檢查|date=中的日期值 (幫助)

[1]

[2]

[3]